Announcements Trials
Browse Landscape

Status

No longer available 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 75Observational 13Expanded_access 2

Sponsor

Cancer Type

Head & Neck 4Thoracic 2Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Lung Neoplasms 9Small Cell Lung Carcinoma 8Pancreatic Neoplasms 7Prostatic Neoplasms 5Ovarian Neoplasms 4Head and Neck Neoplasms 4Colorectal Neoplasms 4Breast Neoplasms 4Sarcoma 3Melanoma 3Carcinoma, Renal Cell 3Carcinoma 3Thyroid Neoplasms 2Neoplasms 2Chondrosarcoma 2Cholangiocarcinoma 2Carcinoma, Medullary 2Carcinoma, Hepatocellular 2Adenocarcinoma of Lung 2Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Non-Small Cell Lung Cancer 1Sarcoma, Synovial 1Rhabdoid Tumor 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Recurrence 1

Interventions

ulixertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Thyroid Neoplasms × Thoracic × Clear all
NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

xCures

Available
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05225259 2024-02-28

Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

Eli Lilly and Company

No longer available
Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡